Scalper1 News
Rare-disease specialist (ALXN) beat Q2 estimates Thursday morning, but its stock dropped as its guidance fell short of expectations amid some big costs. Alexion said that its earnings rose 29% over the year-earlier quarter to $1.44 a share, beating analysts’ consensus by 6 cents, according to Thomson Reuters. Revenue climbed 24% to $636 million, about $8 million above consensus. Alexion lifted and tightened its full-year revenue outlook slightly, Scalper1 News
Scalper1 News